Recently, the biotechnology company Lyndra announced that it has raised US$23 million in a series A financing led by Polaris Partners. Other investment institutions are Quark Venture, GF Securities, Yonghua Capital, Healthlink Capital, Partners Healthcare , Suffolk Equity, etc. The company's new oral drug delivery platform has the characteristics of improving treatment effects and reducing side effects to greatly change patient care and save unnecessary costs for patients and the medical system.

Recently, Artery Network (public number: vcbeat) learned that Lyndra Therapeutics announced the completion of US$55 million in Series B financing to expand the scale of phase II clinical trials of ultra-long-acting oral drugs.

Entering Room 927, Building C, Gongfang Times, located in Lanyuan Road, Huayuan Industrial Zone, Tianjin Sunde Medicine Technology Co., Ltd. A national high-tech enterprise in Tianjin Binhai High-tech Industrial Park.